Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
about
Influenza vaccination in HIV-positive subjects: latest evidence and future perspectiveHIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected childrenSuboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartmentTechnical guidelines for the application of seasonal influenza vaccine in China (2014-2015).Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year GapImmune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.
P2860
Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Safety and immunogenicity of a ...... ted children and young adults.
@ast
Safety and immunogenicity of a ...... ted children and young adults.
@en
type
label
Safety and immunogenicity of a ...... ted children and young adults.
@ast
Safety and immunogenicity of a ...... ted children and young adults.
@en
prefLabel
Safety and immunogenicity of a ...... ted children and young adults.
@ast
Safety and immunogenicity of a ...... ted children and young adults.
@en
P2093
P50
P1433
P1476
Safety and immunogenicity of a ...... cted children and young adults
@en
P2093
Federico Alghisi
Hyppolite Kuekou Tchidjou
Iyadh Douagi
Maria Luisa Romiti
Nadia Mora
Vincenzina Lucidi
P304
P356
10.1016/J.BIOLOGICALS.2011.12.001
P50
P577
2012-01-20T00:00:00Z